Molecular targeted approaches to cancer therapy and prevention using chalcones

Current Cancer Drug Targets

Volumn 14, Issue 2, 2014, Pages 181-200

  Jandial, Danielle D ^a   Blair, Christopher A ^b   Zhang, Saiyang ^c   Krill, Lauren S ^a   Zhang, Yan Bing ^c   Zi, Xiaolin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

Bioactive dietary compounds; Chalcones; Chemoprevention; Molecular targets

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CHALCONE; DEATH RECEPTOR; ESTROGEN RECEPTOR; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; ISOLIQUIRITIGENIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEASOME; PROTEIN MDM2; PROTEIN P53; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; TUBULIN; WNT PROTEIN; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE;

APOPTOSIS; CANCER PREVENTION; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL DEATH; CHEMICAL STRUCTURE; CHEMOPROPHYLAXIS; DRUG ACTIVITY; HUMAN; MITOCHONDRIAL DYNAMICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; MEDICINAL PLANT; METABOLISM; NEOPLASMS; PATHOLOGY; PHYTOTHERAPY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DEATH; CHALCONES; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHYTOTHERAPY; PLANTS, MEDICINAL; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896325215     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140122160515     Document Type: Review

References (136)

1. Orlikova, B.; Tasdemir, D.; Golais, F.; Dicato, M.; Diederich, M. Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr. 2011, 6, 125-147.
2. Yadav, V. R.; Prasad, S.; Sung, B.; Aggarwal, B. B. The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int. Immunopharmacol. 2011, 11, 295-309.
3. Dimmock, J. R.; Elias, D. W.; Beazely, M. A.; Kandepu, N. M. Bioactivities of chalcones. Curr. Med. Chem. 1999, 6, 1125-1149.
4. Bukhari, S. N.; Jasamai, M.; Jantan, I. Synthesis and biological evaluation of chalcone derivatives (mini review). Mini Rev. Med. Chem. 2012, 12, 1394-1403.
5. Dy, G. K.; Adjei, A. A. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J. Clin. 2013, 63, 249-279.
6. Tabernero, J.; Dirix, L.; Schöffski, P.; Cervantes, A.; Lopez-Martin, J. A.; Capdevila, J.; van Beijsterveldt, L.; Platero, S.; Hall, B.; Yuan, Z.; Knoblauch, R.; Zhuang, S. H. A phase I first-inhuman pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17, 6313-6321.
7. Ding, Q.; Zhang, Z.; Liu, J. J.; Jiang, N.; Zhang, J.; Ross, T. M.; Chu, X. J.; Bartkovitz, D.; Podlaski, F.; Janson, C.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L. T.; Graves, B. Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development. J. Med. Chem. 2013, 56 (14), 5979-5983.
8. Stoll, R.; Renner, C.; Hansen, S.; Palme, S.; Klein, C.; Belling, A.; Zeslawski, W.; Kamionka, M.; Rehm, T.; Mühlhahn, P.; Schumacher, R.; Hesse, F.; Kaluza, B.; Voelter, W.; Engh, R. A.; Holak, T. A. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 2001 40, 336-344.
9. Kumar, S. K.; Hager, E.; Pettit, C.; Gurulingappa, H.; Davidson, N. E.; Khan, S. R. Design, synthesis, and evaluation of novel boronicchalcone derivatives as antitumor agents. J. Med. Chem. 2003 46, 2813-2825.
10. Modzelewska, A.; Pettit, C.; Achanta, G.; Davidson, N. E.; Huang, P.; Khan, S. R. Anticancer activities of novel chalcone and bischalcone derivatives. Bioorg. Med. Chem. 2006, 14, 3491-3495.
11. Hsu, Y. L.; Kuo, P. L.; Lin, C. C. Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. Life Sci. 2005, 77, 279-292.
12. Achanta, G.; Modzelewska, A.; Feng, L.; Khan, S. R.; Huang, P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol. Pharmacol. 2006, 70, 426-433.
13. Chen, Z.; Knutson, E.; Wang, S.; Martinez, L. A.; Albrecht, T. Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. Biol. Chem. 2007, 282, 29284-29295.
14. Sasayama, T.; Tanaka, K.; Mizukawa, K.; Kawamura A.; Kondoh, T.; Hosoda, K.; Kohmura, E. Trans-4-lodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo. J. Neurooncol. 2007, 85, 123-132.
15. D'Silva, L.; Ozdowy, P.; Krajewski, M.; Rothweiler, U.; Singh, M.; Holak, T. A. Monitoring the effects of antagonists on proteinprotein interactions with NMR spectroscopy. J. Am. Chem. Soc. 2005, 127, 13220-13226.
16. Lian, Z. Q.; Zhao, D. L.; Zhu, H. B. Hydroxysafflor yellow A upregulates HIF-1alpha via inhibition of VHL and p53 in Eahy 926 cell line exposed to hypoxia. Yao Xue Xue Bao 2008, 43, 484-489.
17. Kamal, A.; Dastagiri, D.; Ramaiah, M. J.; Reddy, J. S.; Bharathi, E. V.; Srinivas, C.; Pushpavalli, S. N.; Pal, D.; Pal-Bhadra, M. Synthesis of imidazothiazole-chalcone derivatives as anticancer and apoptosis inducing agents. Chem. Med. Chem. 2010, 5, 1937-1947.
18. Zhang, Y.; Srinivasan, B.; Xing, C.; Lü, J. A new chalcone derivative (E)-3-(4-methoxyphenyl)-2-methyl-1-(3, 4, 5-trimethoxyphenyl) prop-2-en-1-one suppresses prostate cancer involving p53-mediated cell cycle arrests and apoptosis. Anticancer Res. 2012, 32, 3689-3698.
19. Kim, T. H.; Seo, W. D.; Ryu, H. W.; Seo, H. R.; Jin, Y. B.; Lee, M.; Ji, Y. H.; Park, K. H.; Lee, Y. S. Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production. Chem. Biol. Interact. 2010, 188, 111-118.
20. Tang, Y.; Simoneau, A. R.; Xie, J.; Shahandeh, B.; Zi, X. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev. Res. (Phila Pa) 2008, 1, 439-51.
21. Liu, Z.; Xu, X.; Li, X.; Liu, S.; Simoneau, A. R.; He, F.; Wu, X. R.; Zi, X. KAVA chalcone, Flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model. Cancer Prev. Res. (Phila) 2013, 6, 1365-1375.
22. Kahyo, T.; Ichikawa, S.; Hatanaka, T.; Yamada, M. K.; Setou, M. A novel chalcone polyphenol inhibits the deacetylase activity of SIRT1 and cell growth in HEK293T cells. J. Pharmacol. Sci. 2008, 108, 364-371.
23. Peyrot, V.; Leynadier, D.; Sarrazin, M.; Briand, C.; Rodriquez, A.; Nieto, J. M.; Andreu, J. M. Interaction of tubulin and cellular microtubules with the new antitumor drug MDL 27048. A powerful and reversible microtubule inhibitor. J. Biol. Chem. 1989, 264, 21296-21301.
24. Boumendjel, A.; Boccard, J.; Carrupt, P. A.; Nicolle, E.; Blanc, M.; Geze, A.; Choisnard, L.; Wouessidjewe, D.; Matera, E. L.; Dumontet, C. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J. Med. Chem. 2008, 51, 2307-2310.
25. Ducki, S.; Mackenzie, G.; Greedy, B.; Armitage, S.; Chabert, J. F.; Bennett, E.; Nettles, J.; Snyder, J. P.; Lawrence, N. J. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg. Med. Chem. 2009, 17, 7711-7722.
26. Ducki, S.; Rennison, D.; Woo, M.; Kendall, A.; Chabert, J. F.; McGown, A. T.; Lawrence, N. J. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. Bioorg. Med. Chem. 2009, 17, 7698-7710.
27. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Cara, C. L.; Cruz-Lopez, O.; Preti, D.; Tolomeo, M.; Grimaudo, S.; Di Cristina, A.; Zonta, N.; Balzarini, J.; Brancale, A.; Sarkar, T.; Hamel, E. Design, synthesis, and biological evaluation of thiophene analogues of chalcones. Bioorg. Med. Chem. 2008, 16, 5367-5376.
28. ter Haar, E.; Hamel, E.; Balachandran, R.; Day, B. W. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin. Anticancer Res. 1997, 17, 1861-1869.
29. Zoldakova, M.; Kornyei, Z.; Brown, A.; Biersack, B.; Madarasz, E.; Schobert, R. Effects of a combretastatin A4 analogous chalcone and its Pt-complex on cancer cells: A comparative study of uptake, cell cycle and damage to cellular compartments. Biochem. Pharmacol. 2010, 80, 1487-1496.
30. Tu, H. Y.; Huang, A. M.; Hour, T. C.; Yang, S. C.; Pu, Y. S.; Lin, C. N. Synthesis and biological evaluation of 2',5'-dimethoxychalcone derivatives as microtubule-targeted anticancer agents. Bioorg. Med. Chem. 2010 18, 2089-2098.
31. Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. 1998, 8, 1051-1056.
32. Quintin, J.; Desrivot, J.; Thoret, S.; Le Menez, P.; Cresteil, T.; Lewin, G. Synthesis and biological evaluation of a series of tangeretin-derived chalcones. Bioorg. Med. Chem. Lett. 2009, 19, 167-169.
33. Utsintong, M.; Massarotti, A.; Caldarelli, A.; Theeramunkong, S. Parallel synthesis of "click" chalcones as antitubulin agents. Med. Chem. 2013, 9, 510-516.
34. Vitorović-Todorović, M. D.; Erić-Nikolić, A.; Kolundžija, B.; Hamel, E.; Ristić, S.; Juranić, I. O.; Drakulić, B. J. (E)-4-aryl-4-oxo-2-butenoic acid amides, chalcone-aroylacrylic acid chimeras: design, antiproliferative activity and inhibition of tubulin polymerization. Eur. J. Med. Chem. 2013, 62, 40.
35. Schobert, R.; Biersack, B.; Dietrich, A.; Knauer, S.; Zoldakova, M.; Fruehauf, A.; Mueller, T. Pt(II) complexes of a combretastatin A-4 analogous chalcone: effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression. J. Med. Chem. 2009, 52, 241-246.
36. Ruan, B. F.; Lu, X.; Tang, J. F.; Wei, Y.; Wang, X. L.; Zhang, Y. B.; Wang, L. S.; Zhu, H. L. Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents. Bioorg. Med. Chem. 2011, 19, 2688-2695.
37. Mesenzani, O.; Massarotti, A.; Giustiniano, M.; Pirali, T.; Bevilacqua, V.; Caldarelli, A.; Canonico, P.; Sorba, G.; Novellino, E.; Genazzani, A. A.; Tron, G. C. Replacement of the double bond of antitubulin chalcones with triazoles and tetrazoles: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 2011, 21, 764-768.
38. Dyrager, C.; Wickström, M.; Fridén-Saxin, M.; Friberg, A.; Dahlén, K.; Wallén, E. A.; Gullbo, J.; Grøtli, M.; Luthman, K. Inhibitors and promoters of tubulin polymerization: synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents. Bioorg. Med. Chem. 2011, 19, 2659-2665.
39. Crawford, L. J.; Walker, B.; Irvine, A. E. Proteasome inhibitors in cancer therapy. J. Cell Commun. Signaling 2011, 5, 101-110.
40. McConkey, D. J.; Zhu, K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 2008, 12, 164-179.
41. Bazzaro, M.; Anchoori, R. K.; Mudiam, M. K.; Issaenko, O.; Kumar, S.; Karanam, B.; Lin, Z., Isaksson Vogel, R.; Gavioli, R.; Destro, F.; Ferretti, V.; Roden, R. B.; Khan, S. R., β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J. Med. Chem. 2011, 54, 449-56.
42. Anchoori, R. K.; Khan, S. R.; Sueblinvong, T.; Felthauser, A.; Iizuka, Y.; Gavioli, R.; Destro, F.; Isaksson Vogel, R.; Peng, S.; Roden, R. B.; Bazzaro, M. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One 2011, 6, e23888
43. Issaenko, O. A.; Amerik, A. Y. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle 2012, 11, 1804-1817.
44. Eskander, R. N.; Randall, L. M.; Sakai, T.; Guo, Y.; Hoang, B.; Zi, X. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J. Obstet. Gynaecol. Res. 2012, 38, 1086-1094.
45. Ji, T.; Lin, C.; Krill, L. S.; Eskander, R.; Guo, Y.; Zi, X.; Hoang, B. H. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol. Cancer 2013 12, 55.
46. Hsieh, T. C.; Guo, J.; Kunicki, J.; Lee, M. Y.; Darzynkiewicz, Z.; Wu, J. M. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem. Biophys. Res. Commun. 2004, 322, 263-270.
47. Lee, Y. M.; Lim, D. Y.; Choi, H. J.; Jung, J. I.; Chung, W. Y.; Park, J. H. Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin. J. Med. Food 2009, 12, 8-14.
48. Park, I.; Park, K. K.; Park, J. H.; Chung, W. Y. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. Cancer Lett. 2009, 277, 174-181.
49. De Vincenzo, R.; Ferlini, C.; Distefano, M.; Gaggini, C.; Riva, A.; Bombardelli, E.; Morazzoni, P.; Valenti, P.; Belluti, F.; Ranelletti, F. O.; Mancuso, S.; Scambia, G. In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother. Pharmacol. 2000, 46, 305-312.
50. Ii, T.; Satomi, Y.; Katoh, D.; Shimada, J.; Baba, M.; Okuyama, T.; Nishino, H.; Kitamura, N. Induction of cell cycle arrest and p21(CIP1/WAF1) expression in human lung cancer cells by isoliquiritigenin. Cancer Lett. 2004, 207, 27-35.
51. Park, S.; Gwak, J.; Han, S. J.; Oh, S. Cardamonin Suppresses the Proliferation of Colon Cancer Cells by Promoting β-Catenin Degradation. Biol. Phar. Bull. 2013, 6, 1040-1044.
52. Hsu, Y. L.; Chia, C. C.; Chen, P.J.; Huang, S. E.; Huang, S. C.; Kuo, P. L. Shallot and licorice constituent isoliquiritigenin arrests cell cycle progression and induces apoptosis through the induction of ATM/p53 and initiation of the mitochondrial system in human cervical carcinoma HeLa cells. Mol. Nutr. Food Res. 2009, 53, 826-835.
53. Shen, K. H.; Chang, J. K.; Hsu, Y. L.; Kuo, P. L. Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signalling in human bladder cancer cells. Basic Clin. Pharmacol. Toxicol. 2007, 101, 254-261.
54. Yun, J. M.; Kweon, M. H.; Kwon, H.; Hwang, J. K.; Mukhtar, H. Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgenindependent human prostate cancer cells PC3 and DU145. Carcinogenesis 2006, 27, 1454-1464.
55. Nishimura, R.; Tabata, K.; Arakawa, M.; Ito, Y.; Kimura, Y.; Akihisa, T.; Nagai, H.; Sakuma, A.; Kohno, H.; Suzuki, T. Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Biol. Pharm. Bull. 2007, 30, 1878-1883.
56. Sasayama, T.; Tanaka, K.; Mizukawa, K.; Kawamura, A.; Kondoh, T.; Hosoda, K.; Kohmura, E. Trans-4-lodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo. J. Neurooncol. 2007, 85, 123-132.
57. Echeverria, C.; Santibanez, J. F.; Donoso-Tauda, O.; Escobar, C. A.; Ramirez-Tagle, R. Structural antitumoral activity relationships of synthetic chalcones. Int. J. Mol. Sci. 2009, 10, 221-231.
58. Navarini, A. L.; Chiaradia, L. D.; Mascarello, A.; Fritzen, M.; Nunes, R. J.; Yunes, R. A.; Creczynski-Pasa, T. B. Hydroxychalcones induce apoptosis in B16-F10 melanoma cells via GSH and ATP depletion. Eur. J. Med. Chem. 2009, 44, 1630-1637.
59. Jung, J. I.; Lim, S. S.; Choi, H. J.; Cho, H. J.; Shin, H. K.; Kim, E. J.; Chung, W. Y.; Park, K. K.; Park, J. H. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J. Nutr. Biochem. 2006, 17, 689-696.
60. Sabzevari, O.; Galati, G.; Moridani, M. Y.; Siraki, A.; O'Brien, P. J. Molecular cytotoxic mechanisms of anticancer hydroxychalcones. Chem. Biol. Interact.2004, 148, 57-67.
61. Sun, Z. J.; Chen, G.; Zhang, W.; Hu, X.; Huang, C. F.; Wang, Y. F.; Jia, J.; Zhao, Y. F. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signalregulated kinase. J. Pharmacol. Exp. Ther. 2010, 334, 500-512.
62. Sakai, T.; Eskander, R. N.; Guo, Y.; Kim, K. J.; Mefford, J.; Hopkins, J.; Bhatia, N. N.; Zi, X.; Hoang, B. H. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J. Orthop. Res. 2012, 30, 1045-1050.
63. Zi, X.; Simoneau, A. R. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res.2005, 65, 3479-3486.
64. Tang, Y.; Li, X.; Liu, Z.; Simoneau, A. R.; Xie, J.; Zi, X. Flavokawain B, a kava chalcone, induces apoptosis via upregulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int. J. Cancer 2010, 127, 1758-1768.
65. Kim, N. Butein sensitizes human leukemia cells to apoptosis induced by tumor necrosis factor-related apoptosis inducing ligand (TRAIL). Arch. Pharm. Res. 2008, 31, 1179-1186.
66. Ohtsuki, T.; Kikuchi, H.; Koyano, T.; Kowithayakorn, T.; Sakai, T.; Ishibashi, M. Death receptor 5 promoter-enhancing compounds isolated from Catimbium speciosum and their enhancement effect on TRAIL-induced apoptosis. Bioorg. Med. Chem. 2009, 17, 6748-6754.
67. Yoshida, T.; Horinaka, M.; Takara, M.; Tsuchihashi, M.; Mukai, N.; Wakada, M.; Sakai, T. Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. Environ. Health Prev. Med. 2008, 13, 281-287.
68. Yang, E. B.; Zhang, K.; Cheng, L. Y.; Mack, P. Butein, a specific protein tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 1998, 245, 435-438.
69. Szliszka, E.; Czuba, Z. P.; Mazur, B.; Sedek, L.; Paradysz, A.; Krol, W. Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells. Int. J. Mol. Sci. 2009, 11, 1-13.
70. Szliszka, E.; Czuba, Z. P.; Mazur, B.; Paradysz, A.; Krol, W. Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells. Molecules 2010, 15, 5336-5353.
71. Champelovier, P.; Chauchet, X.; Hazane-Puch, F.; Vergnaud, S.; Garrel, C.; Laporte, F.; Boutonnat, J.; Boumendjel, A. Cellular and molecular mechanisms activating the cell death processes by chalcones: Critical structural effects. Toxicol. In Vitro. 2013, 27, 2305-2315.
72. He, W.; Wang, Q.; Srinivasan, B.; Xu, J.; Padilla, M. T.; Li, Z.; Wang, X.; Liu, Y.; Gou, X.; Shen, H. M.; Xing, C.; Lin, Y. A JNKmediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene 2013, [Epub ahead of print].
73. Robinson, M. W.; Overmeyer, J. H.; Young, A. M.; Erhardt, P. W.; Maltese, W. A. Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death. J. Med. Chem. 2012, 55, 1940-1956.
74. Srinivasan, B.; Johnson, T. E.; Lad, R.; Xing, C. Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities. J. Med. Chem. 2009, 52, 7228-7235.
75. Liu, Y. C.; Hsieh, C. W.; Wu, C. C.; Wung, B. S. Chalcone inhibits the activation of NF-kappaB and STAT3 in endothelial cells via endogenous electrophile. Life Sci. 2007, 80, 1420-1430.
76. Gan, F. F.; Kaminska, K. K.; Yang, H.; Liew, C. Y.; Leow, P. C.; So, C. L.; Tu, L. N.; Roy, A.; Yap, C. W.; Kang, T. S.; Chui, W. K.; Chew, E. H. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity. Antioxid. Redox. Signal. 2013, 19, 1149-1165.
77. Venkateswararao, E.; Sharma, V. K.; Lee, K. C.; Sharma, N.; Park, S. H.; Kim, Y.; Jung, S. H. A SAR study on a series of synthetic lipophilic chalcones as inhibitor of transcription factor NF-κB. Eur. J. Med. Chem. 2012, 54, 379-386.
78. Pandey, M. K.; Sandur, S. K.; Sung, B.; Sethi, G.; Kunnumakkara, A. B.; Aggarwal, B. B. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaB alpha kinase beta on cysteine 179 residue. J. Biol. Chem. 2007, 282, 17340-17350.
79. Zhang, L.; Chen, W.; Li, X. A novel anticancer effect of butein: inhibition of invasion through the ERK1/2 and NF-kappa B signaling pathways in bladder cancer cells. FEBS Lett. 2008, 582, 1821-1828.
80. Kumar, S.; Sharma, A.; Madan, B.; Singhal, V.; Ghosh, B. Isoliquiritigenin inhibits IkappaB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells. Biochem. Pharmacol. 2007, 73, 1602-1612.
81. Harikumar, K. B.; Kunnumakkara, A. B.; Ahn, K. S.; Anand, P.; Krishnan, S.; Guha, S.; Aggarwal, B. B. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood 2009, 113, 2003-2013.
82. Lorenzo, P.; Alvarez, R.; Ortiz, M. A.; Alvarez, S.; Piedrafita, F. J.; de Lera, A. R. Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids. J. Med. Chem. 2008, 51, 5431-5440.
83. Zhou, P.; Gross, S.; Liu, J. H.; Yu, B. Y.; Feng, L. L.; Nolta, J.; Sharma, V.; Piwnica-Worms, D.; Qiu, S. X. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-{kappa}B and MAPK signaling pathways. FASEB J. 2010, 24, 4722-4732.
84. Folmer, F.; Blasius, R.; Morceau, F.; Tabudravu, J.; Dicato, M.; Jaspars, M.; Diederich, M. Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem. Pharmacol. 2006, 71, 1206-1218.
85. Orlikova, B.; Tasdemir, D.; Golais, F.; Dicato, M.; Diederich, M. The aromatic ketone 4'-hydroxychalcone inhibits TNFα-induced NF-κB activation via proteasome inhibition. Biochem. Pharmacol. 2011, 82, 620-631.
86. Hsu, Y. L.; Kuo, P. L.; Tzeng, W. S.; Lin, C. C. Chalcone inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis. Food Chem. Toxicol. 2006, 44, 704-713.
87. Kim, Y. J.; Kim, H. C.; Ko, H.; Amor, E. C.; Lee, J. W.; Yang, H. O. Stercurensin inhibits nuclear factor-κB-dependent inflammatory signals through attenuation of TAK1-TAB1 complex formation. J. Cell Biochem. 2011, 112, 548-558.
88. Reddy, M. V.; Shen, Y. C.; Yang, J. S.; Hwang, T. L.; Bastow, K. F.; Qian, K.; Lee, K. H.; Wu, T. S. New bichalcone analogs as NF-κB inhibitors and as cytotoxic agents inducing Fas/CD95-dependent apoptosis. Bioorg. Med. Chem. 2011, 19, 1895-1906.
89. Shirota, O.; Takizawa, K.; Sekita, S.; Satake, M.; Hirayama, Y.; Hakamata, Y.; Hayashi, T.; Yanagawa, T. Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J. Nat. Prod. 1997, 60, 997-1002.
90. Zhou, J.; Geng, G.; Wu, J. H. Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Invest. New Drug 2010 28, 291-298.
91. Chen, S.; Gao, J.; Halicka, H. D.; Traganos, F.; Darzynkiewicz, Z. Down-regulation of androgen-receptor and PSA by phytochemicals. Int. J. Oncol. 2008, 32, 405-411.
92. Kim, Y. S.; Kumar, V.; Lee, S.; Iwai, A.; Neckers, L.; Malhotra, S. V.; Trepel, J. B. Methoxychalcone inhibitors of androgen receptor translocation and function. Bioorg. Med. Chem. Lett. 2012, 2, 2105-2109.
93. Satomi, Y. Inhibitory effects of 3'-methyl-3-hydroxy-chalcone on proliferation of human malignant tumor cells and on skin carcinogenesis. Int. J. Cancer 1993, 55, 506-514.
94. Wang, Y.; Chan, F. L.; Chen, S.; Leung, L. K. The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase. Life Sci. 2005, 77, 39-51.
95. Ye, L.; Gho, W. M.; Chan, F. L.; Chen, S.; Leung, L. K. Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase. Int. J. Cancer 2009, 124, 1028-1036.
96. Maggiolini, M.; Statti, G.; Vivacqua, A.; Gabriele, S.; Rago, V.; Loizzo, M.; Menichini, F.; Amdò, S. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 2002, 82, 315-322.
97. Rafi, M. M.; Rosen, R. T.; Vassil, A.; Ho, C. T.; Zhang, H.; Ghai, G.; Lambert, G.; DiPaola, R. S. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 2000, 20, 2653-2658.
98. Calliste, C. A.; Le Bail, J. C.; Trouillas, P.; Pouget, C.; Habrioux, G.; Chulia, A. J.; Duroux, J. L. Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res. 2001, 21, 3949-3956.
99. Bois, F.; Beney, C.; Boumendjel, A.; Mariotte, A. M.; Conseil, G.; Di Pietro, A. Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance. J. Med. Chem. 1998, 41, 4161-4164.
100. Bois, F.; Boumendjel, A.; Mariotte, A. M.; Conseil, G.; Di Petro, A. Synthesis and biological activity of 4-alkoxy chalcones: potential hydrophobic modulators of P-glycoprotein-mediated multidrug resistance. Bioorg. Med. Chem. 1999, 7, 2691-2695.
101. Ivanova, A.; Batovska, D.; Engi, H.; Parushev, S.; Ocsovszki, I.; Kostova, I.; Molnar, J. MDR-reversal activity of chalcones. In Vivo, 2008, 22, 379-384.
102. Liu, X. L.; Tee, H. W.; Go, M. L. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg. Med. Chem. 2008, 16, 171-180.
103. Han, Y.; Riwanto, M.; Go, M. L.; Ee, P. L. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues. Eur. J. Pharm. Sci. 2008, 35, 30-41.
104. Qian, F.; Ye, C. L.; Wei, D. Z.; Lu, Y. H.; Yang, S. L. In vitro and in vivo reversal of cancer cell multidrug resistance by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone. J. Chemother. 2005, 17, 309-314.
105. Boumendjel, A.; McLeer-Florin, A.; Champelovier, P.; Allegro, D.; Muhammad, D.; Souard, F.; Derouazi, M.; Peyrot, V.; Toussaint, B.; Boutonnat, J. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer 2009, 9, 242.
106. Gu, X.; Ren, Z.; Tang, X.; Peng, H.; Ma, Y.; Lai, Y.; Peng, S.; Zhang, Y. Synthesis and biological evaluation of bifendatechalcone hybrids as a new class of potential P-glycoprotein inhibitors. Bioorg. Med. Chem. 2012, 20, 2540-2548.
107. Wang, J.; Wang, S.; Song, D.; Zhao, D.; Sha, Y.; Jiang, Y.; Jing, Y.; Cheng, M. Chalcone derivatives inhibit glutathione Stransferase P1-1 activity: insights into the interaction mode of alpha, beta-unsaturated carbonyl compounds. Chem. Biol. Drug Des. 2009, 73, 511-514.
108. Wu, K. C.; McDonald, P. R.; Liu, J.; Klaassen, C. D. Screening of Natural Compounds as Activators of the Keap1-Nrf2 Pathway. Planta. Med. 2014, 80 (1), 97-104.
109. Albini, A.; Dell'Eva, R.; Vene, R.; Ferrari, N.; Buhler, D. R.; Noonan, D. M.; Fassina, G. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J. 2006, 20, 527-529.
110. Kong, Y.; Wang, K.; Edler, M. C.; Hamel, E.; Mooberry, S. L.; Paige, M. A.; Brown, M. L. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg. Med. Chem. 2009 18, 971-977.
111. Lee, Y. S.; Lim, S. S.; Shin, K. H.; Kim, Y. S.; Ohuchi, K.; Jung, S. H. Anti-angiogenic and anti-tumor activities of 2'-hydroxy-4'-methoxychalcone. Biol. Pharm. Bull. 2006, 29, 1028-1031.
112. Nam, N. H.; Kim, Y.; You, Y. J.; Hong, D. H.; Kim, H. M.; Ahn, B. Z. Cytotoxic 2',5'-dihydroxychalcones with unexpected antiangiogenic activity. Eur. J. Med. Chem. 2003, 38, 179-187.
113. Pilatova, M.; Varinska, L.; Perjesi, P.; Sarissky, M.; Mirossay, L.; Solar, P.; Ostro, A.; Mojzis, J.; In vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues. Toxicol. In Vitro 2010, 24, 1347-1355.
114. Chang, H. J.; Yoon, G.; Park, J. S.; Kim, M. H.; Baek, M. K.; Kim, N. H.; Shin, B. A.; Ahn, B. W.; Cheon, S. H.; Jung, Y. D. Induction of apoptosis by the licochalcone E in endothelial cells via modulation of NF-kappaB and Bcl-2 Family. Biol. Pharm. Bull. 2007, 30, 2290-2293.
115. Madan, B.; Batra, S.; Ghosh, B. 2'-hydroxychalcone inhibits nuclear factor-kappaB and blocks tumor necrosis factor-alpha-and lipopolysaccharide-induced adhesion of neutrophils to human umbilical vein endothelial cells. Mol. Pharmacol. 2000, 58, 526-534.
116. Dell'Eva, R.; Ambrosini, C.; Vannini, N.; Piaggio, G.; Albini, A.; Ferrari, N. AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer 2007, 110, 2007-2011.
117. Zhu, X. F.; Xie, B. F.; Zhou, J. M.; Feng, G. K.; Liu, Z. C.; Wei, X. Y.; Zhang, F. X.; Liu, M. F.; Zeng, Y. X. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone), a component from Chinese herbal medicine. Mol. Pharmacol. 2005, 67, 1444-1450.
118. Rizvi, S. U.; Siddiqui, H. L.; Nisar, M.; Khan, N.; Khan, I. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase. Bioorg. Med. Chem. Lett. 2012, 22, 942-944.
119. Funakoshi-Tago, M.; Tago, K.; Nishizawa C, Takahashi, K.; Mashino, T.; Iwata, S.; Inoue, H.; Sonoda, Y.; Kasahara, T. Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation. Biochem. Pharmacol. 2008, 76, 1681-1693.
120. Pandey, M. K.; Sung, B.; Ahn, K. S.; Aggarwal, B. B. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol. Pharmacol. 2009, 75, 525-533.
121. Takahashi, A.; Yamamoto, N.; Murakami, A. Cardamonin suppresses nitric oxide production via blocking the IFN-γ/STAT pathway in endotoxin-challenged peritoneal macrophages of ICR mice. Life Sci. 2011, 89, 337-342.
122. Li, D. D.; Wu, X. Q.; Tang, J.; Wei, X. Y.; Zhu, X. F. ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells. Cancer Biol. Ther. 2009, 8, 739-743.
123. Jung, J. I.; Chung, E.; Seon, M. R.; Shin, H. K.; Kim, E. J.; Lim, S. S.; Chung, W. Y.; Park, K. K.; Park, J. H. Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. Biofactors 2006, 28, 159-168.
124. Zi, X.; Guo, Y.; Simoneau, A. R.; Hope, C.; Xie, J.; Holcombe, R. F.; Hoang, B. H. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgenindependent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 2005, 65, 9762-9770.
125. Cho, M.; Ryu, M.; Jeong, Y.; Chung, Y. H.; Kim, D. E.; Cho, H. S.; Kang, S.; Han, J. S.; Chang, M. Y.; Lee, C. K.; Jin, M.; Kim, H. J.; Oh, S. Cardamonin suppresses melanogenesis by inhibition of Wnt/beta-catenin signaling. Biochem. Biophys. Res. Commun. 2009, 390, 500-505.
126. Sun, Y. W.; Huang, W. J.; Hsiao, C. J.; Chen, Y. C.; Lu, P. H.; Guh, J. H. Methoxychalcone induces cell-cycle arrest and apoptosis in human hormone-resistant prostate cancer cells through PI 3-kinase-independent inhibition of mTOR pathways. Prostate 2010, 70, 1295-1306.
127. Niu, P.; Zhang, Y.; Shi, D.; Chen, Y.; Deng, J. Cardamonin ameliorates insulin resistance induced by high insulin and high glucose through the mTOR and signal pathway. Planta Med. 2013, 79, 452-458.
128. Chen, G.; Hu, X.; Zhang, W.; Xu, N.; Wang, F. Q.; Jia, J.; Zhang, W. F.; Sun, Z. J.; Zhao, Y. F. Mammalian target of rapamycin regulates isoliquiritigenin-induced autophagic and apoptotic cell death in adenoid cystic carcinoma cells. Apoptosis 2012, 17, 90-101.
129. Kim, T. H.; Seo, W. D.; Ryu, H. W.; Seo, H. R.; Jin, Y. B.; Lee, M.; Ji, Y. H.; Park, K. H.; Lee, Y. S. Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production. Chem. Biol. Interact. 2010, 188, 111-118.
130. Kumar, V.; Kumar, S.; Hassan, M.; Wu, H.; Thimmulappa, R. K.; Kumar, A.; Sharma, S. K.; Parmar, V. S.; Biswal, S.; Malhotra, S. V. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. J. Med. Chem. 2011, 54, 4147-4159.
131. Li, Q. S.; Li, C. Y.; Lu, X.; Zhang, H.; Zhu, H. L. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors. Eur. J. Med. Chem. 2012, 50, 288-295.
132. Shin, S. Y.; Yoon, H.; Hwang, D.; Ahn, S.; Kim, D. W.; Koh, D.; Lee, Y. H.; Lim, Y. Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases. Bioorg. Med. Chem. 2013, 21, 7018-24.
133. Yang, Z.; Yang, J.; Jia, Y.; Tian, Y.; Wen, A. Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers. J. Ethnopharmacol. 2009, 124, 635-638.
134. Weber, T. M.; Ceilley, R. I.; Buerger, A.; Kolbe, L.; Trookman, N. S.; Rizer, R. L.; Schoelermann, A. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J. Cosmet. Dermatol. 2006, 5, 227-232.
135. Higuchi, K.; Watanabe, T.; Tanigawa, T.; Tominaga, K.; Fujiwara, Y.; Arakawa, T. Sofalcone, a gastroprotective drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori: a randomized controlled comparative trial with cimetidine, an H2-receptor antagonist. J. Gastroenterol. Hepatol. 2010, 25 (Suppl 1), S155-S160.
136. Wananukul, S.; Chatproedprai, S.; Chunharas, A.; Limpongsanuruk, W.; Singalavanija, S.; Nitiyarom, R.; Wisuthsarewong, W. Randomized, double-blind, split-side, comparison study of moisturizer containing licochalcone A and 1% hydrocortisone in the treatment of childhood atopic dermatitis. J. Med. Assoc. Thai. 2013, 96, 1135-1142.